N/A N=51 Methadone in Pediatric Anesthesiology II
Pain
Primary: Total Opioid Consumption (Morphine Equivalent) — 2.22; 2.37; 3.28 mg/kg — p=.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface · Malignant Peritoneal Mesothelioma · Peritoneal Carcinomatosis
Primary: Recommended Phase 2 Dose (RP2D) (Phase 1) — 5; 0; 4 Participants
N/A N=17 LIBERATE - PRO: Eclipse™ System Registry
Fecal Incontinence · Bowel Dysfunction · Bowel Incontinence
Primary: The St. Mark's (Vaizey) Incontinence Severity Score - Average Change From Baseline Score — -6.58; -5.47; -7.57; -4.64 Score on a Scale
Phase 3 N=1,358 Vitamin D to Improve Outcomes by Leveraging Early Treatment
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
Phase 3 N=107 A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.4; 10.4 percentage points — p=<0.0001
N/A N=79 Symfony Toric Intraocular Lens Visual Outcomes
Cataract Bilateral · Astigmatism Bilateral
Primary: Binocular Distance-corrected Near (40 cm) Visual Acuity. — 0.30; 0.26 diopters
Phase 3 N=555 Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Who Experienced Grade 3 Local Skin Reactions — 22.2; 6.9; 9.8 percentage of participants
Phase 2 N=80 Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: ALS Functional Rating Scale-Revised (ALSFRS-R) — -1.00; -1.26 score on a scale
Phase 4 N=15 Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Parkinson Disease
Primary: Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications. — 8 Participants
Phase 2 N=57 Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
Hepatitis, Alcoholic
Primary: Gastrointestinal Safety Endpoints — 15; 27; 7; 14 Incidents
Phase 3 N=336 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia
Erythrocyte Transfusion · Beta-Thalassemia
Primary: Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24 — 21.0; 4.5 Percentage of participants — p=<0.0001
N/A N=52 Immediate or Delayed Provisionalization in Posterior Healed Sites
Partial Edentulism
Primary: Radiographic Bone Level Mesial to the Implant — 1.26; 1.85 Millimeters — p=0.088
Phase 2 N=44 Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
Hepatic Steatosis
Primary: Absolute Change in Liver Fat Percentage (Randomized Population) — -0.04; -5.37 liver fat percentage — p=0.003
Phase 4 N=66 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
Myocardial Infarction · Diabetes Mellitus · Peripheral Arterial Disease
Primary: Maximal Platelet Aggregation in DM — 65; 78 percentage of aggregation — p=>0.05
Phase 2 N=61 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Advanced Cancers · Lymphoma
Primary: Frequency of DLT — 16; 28; 40 Dose-limiting toxicities